COVID-19 vaccine during pregnancy: it is time to have a fair inclusion of pregnant women in clinical trials. Perinatal Journal 2021;29(3):-
- University of Naples Federico II Naples IT
Elisabetta Gragnano, University of Naples Federico II Naples IT, [email protected]
Manuscript Received: October 06, 2021
Manuscript Accepted: November 05, 2021
Earlyview Date: November 05, 2021
Conflicts of Interest
No conflicts declared.
Covid-19, vaccine, pregnancy
Currently, there is an ongoing debate on COVID-19 vaccines in pregnancy. A Practice Advisory was developed by the American College of Obstetricians and Gynecologists (ACOG) Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group (1). Based on this advisory, ACOG recommended that COVID-19 vaccines should not be withheld from pregnant individuals who meet criteria for vaccination based on the Advisory Committee on Immunization Practices (ACIP) recommended priority groups.
ACOG also stated that COVID-19 vaccines should be offered to lactating patients similar to non-lactating ones. Instead, before the recommendation stated by ACOG, the World Health Organization (WHO) admitted that while pregnancy puts women at higher risk of severe COVID-19, very little data are available to assess vaccine safety in pregnancy.
On January 8 2021, the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has issued its policy recommendations for the rollout of the first COVID-19 vaccine approved for emergency use, the Pfizer-BioNTech COVID-19 vaccine (2). In this reccomendations the SAGE stated clearly that, due to insufficient data, ‘WHO does not recommend the vaccination of pregnant women at this time’ (2). Surprisingly, the same group published Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 (3) where stated, on January 26, 2021 that ‘Based on what we know about this kind of vaccine, we don’t have any specific reason to believe there will be specific risks that would outweigh the benefits of vaccination for pregnant women. For this reason, those pregnant women at high risk of exposure to SARS-CoV-2 (e.g. health workers) or who have comorbidities which add to their risk of severe disease, may be vaccinated in consultation with their health care provider.’ (3).
The development of drugs and vaccine is a slow process, and all the phases involved in their development are necessary to test for safety and efficacy in different subgroups of population. Unfortunately, pregnant women are often underrepresented in clinical research and excluded from trials solely for their pregnancy status. In fact, pregnant women have been excluded from all trials on COVID-19 vaccine (4).
Conflicting recommendations are confusing for both health care providers and for pregnant women and may also incite cospiration and no vax theories. In our opinion, therefore, first, evidence-based data are needed, such as urgent call for pregnant women to be included in appropriately designed vaccine trials and clinical studies. Moreover, we recommend to all societies to be consistent in recommendations and publish joint advisories.
1-ACOG. Vaccinating Pregnant and Lactating Patients Against COVID-19. Practice Advisory. December 2020
2-WHO’s Strategic Advisory Group of Experts on Immunization (SAGE). Who can take the Pfizer-BioNTech COVID-19 vaccine? Available at https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine
3-WHO’s Strategic Advisory Group of Experts on Immunization (SAGE). The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know
4-Saccone G, Zullo F, Di Mascio D. COVID-19 vaccine in pregnant women: not so far! The importance of counselling and the need for evidence-based data. Am J Obstet Gynecol. 2021